TRDA
vs
S&P 500
TRDA
S&P 500
Over the past 12 months, TRDA has underperformed S&P 500, delivering a return of -37% compared to the S&P 500's +14% growth.
Stocks Performance
TRDA vs S&P 500
Performance Gap
TRDA vs S&P 500
Performance By Year
TRDA vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Entrada Therapeutics Inc
Glance View
Entrada Therapeutics, Inc. operates as a biotechnology company. The company is headquartered in Boston, Massachusetts and currently employs 114 full-time employees. The company went IPO on 2021-10-29. The firm's EEV therapeutics are designed to enable the efficient intracellular delivery of a wide range of therapeutics into a variety of organs and tissues with an improved therapeutic index. Through its EEV Platform, Entrada is building a development portfolio of oligonucleotide-, antibody- and enzyme-based programs for the potential treatment of neuromuscular diseases, immunology, oncology and diseases of the central nervous system. The firm's lead oligonucleotide programs include ENTR-601-44 targeting Duchenne muscular dystrophy (DMD), and a follow-on program targeting myotonic dystrophy type 1 (DM1). DMD is a monogenic X-linked disease caused by mutations in the DMD gene.